- Home
- PMVP vs IPSC Comparison
PMVP vs IPSC Comparison
Compare PMVP & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- IPSC
- Stock Information
- Founded
- PMVP 2013
- IPSC 2019
- Country
- PMVP United States
- IPSC United States
- Employees
- PMVP N/A
- IPSC N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- PMVP Health Care
- IPSC Health Care
- Exchange
- PMVP Nasdaq
- IPSC Nasdaq
- Market Cap
- PMVP 55.1M
- IPSC 49.6M
- IPO Year
- PMVP 2020
- IPSC 2021
- Fundamental
- Price
- PMVP $1.31
- IPSC $0.62
- Analyst Decision
- PMVP Strong Buy
- IPSC Strong Buy
- Analyst Count
- PMVP 1
- IPSC 5
- Target Price
- PMVP $5.00
- IPSC $3.33
- AVG Volume (30 Days)
- PMVP 265.0K
- IPSC 956.1K
- Earning Date
- PMVP 08-07-2025
- IPSC 08-07-2025
- Dividend Yield
- PMVP N/A
- IPSC N/A
- EPS Growth
- PMVP N/A
- IPSC N/A
- EPS
- PMVP N/A
- IPSC N/A
- Revenue
- PMVP N/A
- IPSC $114,898,000.00
- Revenue This Year
- PMVP N/A
- IPSC $1,064.82
- Revenue Next Year
- PMVP N/A
- IPSC N/A
- P/E Ratio
- PMVP N/A
- IPSC N/A
- Revenue Growth
- PMVP N/A
- IPSC 8286.72
- 52 Week Low
- PMVP $0.81
- IPSC $0.34
- 52 Week High
- PMVP $1.82
- IPSC $3.29
- Technical
- Relative Strength Index (RSI)
- PMVP 68.35
- IPSC 52.73
- Support Level
- PMVP $0.96
- IPSC $0.52
- Resistance Level
- PMVP $1.36
- IPSC $0.57
- Average True Range (ATR)
- PMVP 0.09
- IPSC 0.03
- MACD
- PMVP 0.02
- IPSC -0.00
- Stochastic Oscillator
- PMVP 79.80
- IPSC 70.86
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.